Compare ICFI & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | MPLT |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2006 | N/A |
| Metric | ICFI | MPLT |
|---|---|---|
| Price | $76.74 | $38.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $99.25 | $32.67 |
| AVG Volume (30 Days) | 283.4K | ★ 477.1K |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $1,229,162,000.00 | N/A |
| Revenue This Year | $4.12 | N/A |
| Revenue Next Year | $5.33 | N/A |
| P/E Ratio | $68.16 | ★ N/A |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $58.83 | $12.24 |
| 52 Week High | $101.71 | $39.91 |
| Indicator | ICFI | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 61.86 | 65.36 |
| Support Level | $73.89 | $26.20 |
| Resistance Level | $83.85 | N/A |
| Average True Range (ATR) | 3.22 | 2.80 |
| MACD | 0.68 | 0.66 |
| Stochastic Oscillator | 79.94 | 83.61 |
ICF International Inc provides professional services and technology-based solutions, including management, technology and policy consulting and implementation services, to government and commercial clients in the U.S. and internationally. Its government clients include U.S. federal agencies, state and local governments and international governments, as well as commercial clients inside and outside the U.S. It supports clients in Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs; and Security and Other Civilian and Commercial markets. The company delivers services across the life cycle of a policy, program or project through Advisory Services, Program Implementation, Analytics Services, Digital Services and Engagement Services.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.